Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466427 | 0.76 | OPRK1 (0.33) | OPRK1KMT2AMETAP2 | |
| SCHEMBL144184 | 0.69 | METAP2 (0.48) | OPRK1KMT2AMETAP2 | |
| SCHEMBL9799101 | 0.67 | ACHE (0.31) | ACHE | |
| SCHEMBL9172751 | 0.66 | MMP2 (0.49) | KMT2AMETAP2 | |
| SCHEMBL6844002 | 0.63 | CCR1 (0.43) | KMT2AACHEMETAP2 | |
| SCHEMBL9776373 | 0.62 | — | — | |
| SCHEMBL30082244 | 0.62 | METAP2 (0.63) | KMT2AACHEMETAP2 | |
| SCHEMBL672744 | 0.62 | METAP2 (0.63) | KMT2AACHEMETAP2 | |
| SCHEMBL8467497 | 0.61 | METAP2 (0.48) | KMT2AACHEMETAP2 | |
| SCHEMBL8840923 | 0.61 | MYC (0.37) | OPRK1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019075-B9 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1019075-B1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7105701-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1019075-B9 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1019360-A4 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1019360-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999064035-A9 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999064034-A9 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-1003540-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999064031-A9 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999064035-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064031-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064034-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | OPRK1 28/4885KMT2A 4173/4885ACHE 734/4885 |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | OPRK1 26/4885KMT2A 4098/4885ACHE 682/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | OPRK1 28/4885KMT2A 4173/4885ACHE 734/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | OPRK1 28/4885KMT2A 4173/4885ACHE 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.